NCT01310244 - MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Stage IV Non-small Cell Lung Cancer

Interventions

DRUG

Belinostat, Carboplatin, Paclitaxel

Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.

Trial Locations (4)

33426

University Cancer Insitute, Boynton Beach

35805

Clearview Cancer Institute (CCI), Huntsville

63110

Washington University School of Medicine, St Louis

90403

Sarcoma Oncology Center, Santa Monica